Page 1

AmerisourceBergen Amerisource Bergen Reports Fiscal 2021 Third Quarter Results 8/4/2021 Revenues of $ 53.4 billion for the Third Quarter , a 17.7 Percent Increase Year - Over - Year Third Quarter GAAP Diluted EPS of $ 1.40 and Adjusted Diluted EPS of $ 2.16 Adjusted Diluted EPS Guidance Range Raised to $ 9.15 to $ 9.30 for Fiscal 2021 CONSHOHOCKEN , Pa .-- ( BUSINESS WIRE ) -- Amerisource Bergen Corporation ( NYSE : ABC ) today reported that in its fiscal year 2021 third quarter ended June 30 , 2021 , revenue increased 17.7 percent year - over - year to $ 53.4 billion . On the basis of U.S. generally accepted accounting principles ( GAAP ) , diluted earnings per share ( EPS ) was $ 1.40 for the June quarter of fiscal 2021 , compared to $ 1.41 in the prior year quarter . Adjusted diluted EPS , which is a non - GAAP measure that excludes items described below , increased 16.8 percent to $ 2.16 in the fiscal third quarter . Amerisource Bergen is updating its outlook for fiscal year 2021. The Company does not provide forward - looking guidance on a GAAP basis , as discussed below in Fiscal Year 2021 Expectations . Adjusted diluted EPS guidance has been raised from the previous range of $ 8.90 to $ 9.10 to a range of $ 9.15 to $ 9.30 , reflecting growth of 16 percent to 18 percent versus the previous fiscal year . " During the third quarter , Amerisource Bergen continued to capitalize on our differentiated , pharmaceutical - centric value proposition and successfully executed on our key strategic initiatives including completing the acquisition of Alliance Healthcare , " said Steven H. Collis , Chairman , President and Chief Executive Officer of Amerisource Bergen . " We are proud of the execution by our teams to deliver these results and pleased to increase financial guidance for fiscal 2021 to reflect the continued strong performance across our businesses . " " Amerisource Bergen's purpose - driven teams continue to provide critical pharmaceutical distribution services and innovative pharmaceutical services to customers across our global footprint , " Mr. Collis continued . " By providing differentiated value to our stakeholders , focusing on our customers , expanding on our leadership in specialty distribution , and executing , innovating , and supporting pharmaceutical innovation globally , we are well positioned to create long - term stakeholder value as we remain united in our responsibility to create healthier futures . " Third Quarter Fiscal Year 2021 Summary Results Revenue Gross Profit Operating Expenses Operating Income Interest Expense , Net Effective Tax Rate GAAP $ 53.4B $ 1.9B $ 1,267M $ 621M $ 51M 48.5 % Adjusted ( Non - GAAP ) $ 53.4B $ 1.6B $ 996M $ 631M $ 51M 21.0 % 1